India · Delayed Price · Currency is INR Shaily Engineering Plastics Earnings Call Transcripts
Fiscal Year 2027
-
Healthcare segment led strong Q1 FY 2027 growth, with revenue up 14% and EBITDA up 18% year-over-year. Pen injector capacity expansion and new project wins position the company to exceed full-year guidance, despite ongoing supply chain and market volatility.
Fiscal Year 2026
-
Q4 and FY 2026 saw strong revenue and profit growth, led by a 139% surge in healthcare revenue and successful launches in regulated markets. New business wins in semiconductors and consumer electronics, along with disciplined capital planning, position the company for continued expansion.
-
Q3 FY 2026 delivered 27% revenue growth and 43% EBITDA growth, led by Healthcare's 139% YoY surge and new global contracts. Major capacity expansions in India and Abu Dhabi are underway, with strong order backing and margin normalization expected as high-speed lines ramp up.
-
Q2 FY 2026 saw 34% revenue growth and a 163% surge in healthcare, with EBITDA margins rising to 31.8%. Capacity expansion and new device launches support strong outlook, while regulatory and competitive risks are actively managed.
-
Q1 FY 2026 saw 38% revenue growth and a 181% surge in healthcare segment revenue, with EBITDA margin rising to 28.5%. Healthcare capacity is expanding to 70–75 million pens by early FY 2027, with strong customer commitments and new product launches driving future growth.
Fiscal Year 2025
-
FY 2025 saw 22% revenue growth and 350 bps EBITDA margin expansion, led by a 53% surge in healthcare segment revenues and strong gains in consumer and industrial segments. Pen capacity is set to nearly double, with robust outlook for IP-led platforms and continued margin improvement.
-
Q3 FY25 saw 25% revenue growth and margin expansion, led by a 52% surge in healthcare. Capacity expansion is underway, with medical devices expected to reach 30% of revenues in three years. New contracts and global initiatives support a positive outlook.
-
Q2 FY 2025 saw 22% revenue growth and a 94% surge in healthcare, with margins and profitability sharply higher year-on-year. Major capacity expansions are underway in drug delivery devices, with medical devices targeted to reach 25% of revenues in three years.
-
Q1 FY25 saw 14% revenue growth, margin expansion, and strong PAT increase, driven by new orders in healthcare and industrial segments. Major insulin pen order and robust Shaily U.K. pipeline support future growth, with capacity expansion planned.